Qurient Co., Ltd.
KKRX:11518019,470.00
KRW
-730.00
(-3.61%)
ISIN
KR7115180002
Return %
Stock
S&P 500
1Y
7.60
13.14
3Y
614.35
80.78
5Y
1.61
67.74
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- CEO
- Ki-Yean Nam
- Full Time Employees
- 32
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- Seongnam-si South Korea
- IPO Date
- Oct 29, 2015
- Website
- qurient.com
- Similar Companies
- Business
- Qurient Co., Ltd. is a South Korea-based clinical-stage biotechnology company that engages in the research and development of novel small-molecule therapeutics and antibody-drug conjugates (ADCs) for oncology, inflammatory diseases, and infectious disorders. The company operates through a virtual Network R&D business model, advancing drug candidates from discovery through clinical proof-of-concept by leveraging a global network of scientific institutions, contract research organizations, and corporate partners. Its core clinical and preclinical development pipeline comprises oncology candidates, including Mocaciclib (Q901), a selective cyclin-dependent kinase 7 (CDK7) inhibitor in Phase 1/2 clinical trials as a monotherapy and in combination with endocrine therapies and pembrolizumab for solid tumors and HR+/HER2- breast cancer; Adrixetinib (Q702), an orally bioavailable triple kinase inhibitor targeting AXL, MER, and CSF1R in Phase 1/2 evaluation for solid tumors, acute myeloid leukemia (AML), and chronic graft-versus-host disease (cGvHD); and QP101, a HER2-targeted dual-payload ADC for solid tumors. The company's pipeline also encompasses anti-infective and immunology programs, featuring Telacebec (Q203), a first-in-class cytochrome bc1 complex inhibitor indicated for pulmonary tuberculosis and non-tuberculous mycobacterial (NTM) infections; and Q301, a topical 5-lipoxygenase (5-LO) inhibitor for the treatment of atopic dermatitis. Through its German subsidiary and joint venture, QLi5 Therapeutics GmbH, Qurient develops novel non-covalent proteasome inhibitors and proteasome-inhibitor-based ADC platforms for hematologic malignancies and autoimmune conditions. In recent major corporate developments, DongKoo Bio & Pharma Co., Ltd. made a KRW 10 billion strategic investment to become Qurient's largest shareholder, strengthening financial backing for global clinical progression; the company advanced clinical collaborations evaluating its lead oncology assets in combination with anti-PD-1 immunotherapies; and it expanded its development focus into next-generation ADC platforms and targeted degrader technologies. Founded in 2008 as a commercial spin-off from Institut Pasteur Korea, Qurient Co., Ltd. is headquartered in Seongnam-si, South Korea, with international research and clinical development operations spanning North America and Europe.